AbbVie Inc | ABBV.USX
United States - USD

Stock Exchange: NYSE

Symbol: ABBV

Sector: Healthcare

Industry: Drug Manufacturers - General

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc Stats

Previous close:Daily change:
203.87-0.16%
52-Week High:52-Week Low:
207.32135.85
Market Cap:Beta:
359.5 Billion0.62

AbbVie Inc Key Financials

P/E Ratio:Revenues:Revenue Growth:Gross Margin:
70.923455.5 Billion3.80%70.14%
Dividend Yield:Net Income:Earnings Growth:Net Income Margin:
3.22%5.1 Billion-12.00%9.22%
P/E Ratio:Revenues:
70.923455.5 Billion
Dividend Yield:Net Income:
3.22%5.1 Billion
Revenue Growth:Gross Margin:
3.80%70.14%
Earnings Growth:Net Income Margin:
-12.00%9.22%
ParametersStocks Investing
Stock CurrencyUSD
Dividend PayingYes
Fractional SharesYes
Maximum Shares100 Shares
Tick value per 1 share0.01 USD
Trading Commission0%
Minimum Price Increment0.01
Limit and Stop Levels0.0
Negative balance protectionNo
Swap free days allowanceN/A
Own the underlying AssetNo
Platform symbolABBV.USX
Disclaimer: This material is provided by third-party data sources as a general marketing communication for information purposes only and does not constitute an independent investment research. Nothing in this communication contains, or should be considered as containing, an investment advice or an investment recommendation or a solicitation for the purpose of buying or selling of any financial instrument. All information provided is gathered from reputable sources and any information containing an indication of past performance is not a guarantee or reliable indicator of future performance. Users acknowledge that any investment in CFDs and Physical Stocks products is characterized by a certain degree of uncertainty and that any investment of this nature involves a high level of risk for which the users are solely responsible and liable. We assume no liability for any loss arising from any investment made based on the information presented here.
High Risk Investment Warning: Contracts for Difference (‘CFDs’) are complex financial products that are traded on margin. Trading CFDs carries a high degree of risk. It is possible to lose all your capital. These products may not be suitable for everyone and you should ensure that you understand the risks involved. Seek independent expert advice if necessary and speculate only with funds that you can afford to lose. Please think carefully whether such trading suits you, taking into consideration all the relevant circumstances as well as your personal resources. We do not recommend clients posting their entire account balance to meet margin requirements. Clients can minimise their level of exposure by requesting a change in leverage limit. For more information please refer to HYCM’s Risk Disclosure.
Disclaimer: The content of this page is for information purposes only and it is not intended as a recommendation or advice. Any indication of past performance or simulated past performance included in advertisements published by HYCM is not a reliable indicator of future results. The customer carries the sole responsibility for all the businesses or investments that are carried out at HYCM.
Regional Restrictions: We do not offer our services to residents of certain jurisdictions such as Afghanistan, Belgium, Hong Kong, the United States of America and some other regions. For more information please refer to our
Help Center

HYCM Limited is authorized and regulated under the Dubai Financial Services Authority with license number F000048.

Copyright © 2024 HYCM.